查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1868923

核酸療法CDMO市場按治療類型、服務類型、治療應用和最終用戶分類－2025-2032年全球預測

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type, Service Type, Therapeutic Applications, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核酸療法的合約開發和生產組織 (CDMO) 市場將成長至 261.4 億美元，複合年成長率為 11.71%。

關鍵市場統計數據
基準年 2024 107.7億美元
預計年份：2025年 120億美元
預測年份 2032 261.4億美元
複合年成長率 (%) 11.71%

隨著CDMO在加速發展的策略角色中扮演越來越重要的角色，它們將助力複雜核酸療法的開發，以滿足日益成長的科學和監管需求。

核酸治療藥物的合約開發與生產（CDMO）領域已進入技術快速融合、戰略重要性日益凸顯的階段，這對研發方和合約合作夥伴都至關重要。治療模式、生產平台和監管要求的最新進展，已使CDMO從單純的供應商轉變為對專案進度和臨床可行性具有重大影響的策略合作夥伴。隨著研發方不斷探索日益複雜的結構，包括修飾寡核苷酸、病毒載體和脂質奈米顆粒製劑，對專業製程知識、嚴格的品管和靈活的生產能力的需求也日益成長。

揭示正在改變核酸治療領域研發、生產實踐、監管預期和夥伴關係模式的多方面顛覆性力量

核酸療法正在重塑治療模式，這項變革正推動研發、生產和商業化等各環節發生連鎖反應。技術創新正在推動分子設計、生產和測試方式的模式轉移，模組化和連續生產方法在許多應用中取代了傳統的間歇式生產。同時，數位化製程控制和先進的分析技術正在加強品質系統和製程理解的基礎。這些變化正在拓展合約研發生產機構（CDMO）所需的能力範圍，要求其投資於專用設備、即時監控能力和多學科人才。

評估2025年關稅調整對核酸治療供應鏈的採購、供應商合格和營運風險管理的影響

美國2025年關稅的實施和調整為核酸治療藥物生產的供應和成本模式引入了新的變數。影響進口原料、特殊試劑和某些生產設備的關稅措施迫使生產商和贊助公司重新評估籌資策略，並加快替代供應商的資格認證。因此，採購團隊正在加強對供應商韌性和地理多元化的審查，而生產負責人則在權衡近岸外包、在岸外包和維持海外合作關係之間的利弊。

從模式、服務類型、應用和最終用戶群等方面推導出策略意義，以指導能力投資和夥伴關係關係結構。

透過沿著多個細分維度分析需求和產能，可以更清楚地了解市場格局。從治療方法類型來看，DNA療法和RNA療法之間的差異對生產流程、分析測試範式和監管環節都具有重要意義。 RNA療法需要專門的製劑技術和低溫運輸能力，而DNA療法在上游工程和下游純化方面則面臨獨特的挑戰。從服務角度來看，分析測試和品管、生產/包裝/分銷以及製程開發/最佳化之間的相互作用決定了價值所在。能夠整合端到端服務的機構可以縮短週期並減少交接環節，而精通高技術任務和方法開發的專業技能仍然至關重要。

解讀區域生態系統、法規結構與能力發展對美洲、歐洲、中東和非洲以及亞太地區CDMO戰略定位的影響

區域趨勢持續影響CDMO產業的策略決策，每個區域的需求和產能都受到不同因素的影響。在美洲，蓬勃發展的生物技術生態系統、創業投資投資以及大量後期臨床計畫推動了對可擴展生產和嚴格監管合規性的需求。這種環境促使申辦方和生產合作夥伴在臨床到商業化過渡計畫中密切合作，這就要求對符合GMP標準的設施、監管事務專業知識和供應鏈韌性進行投資。

了解CDMO如何透過技術深度、一體化服務和客戶客製化的商業結構來脫穎而出，以及它們所採用的競爭和夥伴關係模式。

在核酸治療生態系中，企業間的競爭日益凸顯，其競爭優勢體現在對治療模式的深入了解、綜合服務能力以及透過成熟的監管實踐降低臨床轉化風險的能力。領先的供應商正透過投資平台技術來實現差異化，這些技術能夠加快製程開發速度、提高產品品質並簡化規模化生產路徑。單純的生產能力已不再是決定性因素；相反，那些將完善的品質系統、先進的分析技術以及成功的技術轉移經驗相結合的企業，才能獲得競爭優勢。

經營團隊為提升核酸治療藥物研發的可靠性，必須解決以下實際策略問題：加強夥伴關係、提高供應鏈韌性、數位化品管和人力資源發展。

產業領導者和專案發起人應採取一系列切實可行的措施，使其營運、夥伴關係和投資計畫與核酸療法開發不斷變化的實際情況相適應。首先，應優先建立聯合開發框架，正式確立發起人和生產商之間的早期合作，以加速製程轉移並最大限度地減少後續環節的意外情況。設定共同的里程碑和決策節點有助於明確預期，並減少規模化生產過程中的返工。其次，應投資於供應鏈透明度及關鍵原料及特殊試劑的雙源籌資策略，以因應貿易政策變化及單一來源依賴所帶來的風險。儘早啟動供應商選擇流程至關重要，以便在需要替代供應商時縮短研發週期。

我們將解釋一種混合方法研究設計，該設計結合了專家訪談、技術檢驗和三角驗證的二級資訊來源，以確保研究結果的實用性和有效性。

基礎調查方法整合了多種證據來源，以確保提供可靠的實踐見解。二級研究包括對科學文獻、監管指導文件、行業白皮書和技術標準的系統性回顧，以建立技術和監管基礎框架。一級研究包括對製造企業高管、製程科學家、監管專家、採購高管和專案經理進行結構化訪談，以收集有關營運挑戰、供應商績效和夥伴關係動態的第一手資訊。這些定性洞見輔以技術檢驗工作，包括近期技術轉移案例分析、可比性研究和製程放大實例。

從發現到交付，核酸藥物能否成功取決於能力、夥伴關係和供應鏈韌性的策略協調。

由於科學創新、不斷變化的監管要求和營運需求的轉變，核酸藥物生產格局正處於變革之中。那些認知到夥伴關係關係策略意義，並投資於卓越分析、適應性生產以及貫穿彈性供應鏈的整合能力的企業，將更有能力將科學進步轉化為可靠的臨床和商業供應。轉型挑戰，例如關稅驅動的供應調整、區域產能重組以及對先進分析技術的需求，既給營運帶來挑戰，也為能夠提供清晰且檢驗的、可降低風險的規模化生產路徑的企業帶來機遇。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 具備最佳化脂質奈米顆粒配方能力的可擴展mRNA生產平台的需求日益成長
  • 透過將自動化高通量篩檢整合到寡核苷酸生產工作流程中來加速製程開發
  • 採用連續生產製程可提高質體DNA產量的穩定性並降低污染風險。
  • CDMO與生技公司進行策略合作，共同開發以CRISPR-Cas系統為基礎的基因編輯療法。
  • 投資於專為病毒載體生產而設計的模組化一次性生物反應器系統，以支援基因治療研發管線。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 核酸療法CDMO市場（依治療類型分類）

  • DNA療法
  • RNA療法

9. 核酸治療藥物CDMO市場依服務類型分類

  • 分析測試和品管
  • 製造業
  • 包裝/配送
  • 製程開發與最佳化

第10章：核酸治療藥物CDMO市場（依治療應用分類）

  • 遺傳性疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學
  • 罕見疾病

第11章 核酸治療藥物CDMO市場（依最終用戶分類）

  • 學術和研究機構
  • 生技公司
  • 製藥公司

第12章：核酸療法CDMO市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 核酸治療藥物CDMO市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國核酸治療藥物CDMO市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AGC Biologics Inc.
    • Agilent Technologies, Inc.
    • Ajinomoto Bio-Pharma Services
    • Almac Group Ltd.
    • Biomay AG
    • BioSpring GmbH
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • CordenPharma International GmbH
    • Creative Biogene
    • Danaher Corporation
    • Eurofins Scientific SE
    • Evonik Industries AG
    • GenScript Biotech Corporation
    • Lonza Group Ltd.
    • Polypeptide Group AG
    • Recipharm AB
    • Rentschler Biopharma SE
    • Samsung Biologics
    • The Scripps Research Institute
    • Touchlight Group
    • Univercells Group
    • WuXi AppTec Co., Ltd.
Product Code: MRR-CA7E340319CD

The Nucleic Acid Therapeutics CDMO Market is projected to grow by USD 26.14 billion at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.77 billion
Estimated Year [2025] USD 12.00 billion
Forecast Year [2032] USD 26.14 billion
CAGR (%) 11.71%

Framing the evolving strategic role of CDMOs in enabling complex nucleic acid therapeutic development amid accelerating scientific and regulatory demands

The nucleic acid therapeutics contract development and manufacturing landscape has entered a phase defined by rapid technological convergence and elevated strategic importance for both developers and contract partners. Recent advances in therapeutic modalities, manufacturing platforms, and regulatory expectations have elevated CDMOs from service vendors to strategic collaborators that materially influence program timelines and clinical viability. As developers pursue increasingly complex constructs, including modified oligonucleotides, viral vectors, and lipid nanoparticle formulations, demand for specialized process knowledge, stringent quality control, and adaptive manufacturing capacity has intensified.

Consequently, organizations that provide integrated capabilities spanning process development, analytical rigor, and scale-ready manufacturing are being evaluated not only on cost and capacity but also on agility, regulatory track record, and partnership models that de-risk development pathways. Stakeholders must therefore reassess their sourcing strategies, technology roadmaps, and compliance frameworks to reflect an environment where speed-to-clinic and supply continuity are as critical as technical excellence. Moving forward, the interplay between scientific innovation and pragmatic manufacturing constraints will determine which programs advance efficiently and which face protracted development timelines, making it imperative for executives to align commercial strategy with operational realities across the value chain.

Unpacking the multidimensional disruptive forces altering R&D, manufacturing modalities, regulatory expectations, and partnership models across nucleic acid therapeutics

Nucleic acid therapeutics are reshaping therapeutic paradigms, and with that transformation comes a cascade of shifts across R&D, manufacturing, and commercialization. Technological innovation is driving paradigm changes in how molecules are designed, produced, and tested; modular and continuous manufacturing approaches are replacing batch orthodoxy in many applications, while digital process controls and advanced analytics increasingly underpin quality systems and process understanding. These shifts have broadened the competency set required of contract development and manufacturing organizations, requiring investments in specialized equipment, real-time monitoring capabilities, and cross-disciplinary talent.

At the same time, regulatory expectations have matured, emphasizing lifecycle quality management, data integrity, and platform-based comparability. This maturation is influencing project planning and capitalization decisions and is prompting greater early-stage alignment between developers and manufacturers on quality by design principles. Moreover, commercial pressures are altering partnership structures: strategic alliances, risk-sharing arrangements, and capacity reservation models are becoming more common as sponsors seek to secure prioritized throughput and mitigate supply chain risk. Taken together, these transformative shifts mean that CDMOs must evolve beyond transactional relationships to become long-term strategic partners that co-design processes, anticipate regulatory challenges, and scale capabilities in lockstep with evolving modality requirements.

Assessing how tariff adjustments in 2025 have recalibrated sourcing, supplier qualification, and operational risk management across the nucleic acid therapeutics supply chain

The imposition and adjustment of tariffs by the United States in 2025 have introduced new variables into the supply and cost calculus for nucleic acid therapeutics manufacturing. Tariff measures that affect imported raw materials, specialized reagents, and certain manufacturing equipment have prompted manufacturers and sponsors to reassess sourcing strategies and to accelerate efforts to qualify alternative suppliers. As a result, procurement teams have increased scrutiny of supplier resilience and geographic diversification while manufacturing planners evaluate the trade-offs between nearshoring, onshoring, and maintaining offshore partnerships.

In practice, these tariff-driven dynamics have influenced capital allocation decisions and timetable assumptions. Sponsors that previously relied on a global sourcing model for key inputs have initiated dual-sourcing strategies and have elevated buffer management to preserve continuity for critical campaigns. Investments in supplier qualification and audits have increased, as firms seek to validate localized supply chains. Moreover, some organizations have advanced plans for regional capacity expansion to reduce exposure to cross-border cost volatility and mitigate potential lead-time disruptions. Regulatory dossiers and quality control frameworks have had to accommodate the introduction of new supplier-origin materials, requiring targeted comparability studies and additional documentation. While tariffs have not altered the scientific principles behind modality development, they have reshaped operational risk management and have heightened the strategic importance of supply chain transparency, supplier performance metrics, and contractual protections that address cross-border trade risk.

Deriving strategic implications from modality, service type, application, and end-user segmentation to target capability investments and partnership structures

A granular view of the landscape emerges when analyzing demand and capability along multiple segmentation axes. When viewed through the lens of therapeutic type, distinctions between DNA therapeutics and RNA therapeutics materially influence manufacturing workflows, analytical testing paradigms, and regulatory touchpoints; RNA modalities often demand specialized formulation expertise and cold-chain considerations, while DNA-based approaches entail distinct upstream and downstream purification challenges. From the perspective of service type, the interplay between analytical testing and quality control, manufacturing, packaging and distribution, and process development and optimization defines where value accrues; organizations that integrate end-to-end services can shorten timelines and reduce handoffs, while niche specialists retain relevance for highly technical tasks and method development.

Considering therapeutic application highlights divergent demand drivers: genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders each present unique payload requirements, dosing regimens, and clinical development risk profiles, which in turn shape manufacturing complexity and demand for tailored assays. Finally, end-user segmentation-academic and research institutes, biotechnology firms, and pharmaceutical companies-reveals differing expectations for flexibility, timelines, and regulatory support; academic partners often require adaptable, lower-volume services focused on method establishment, biotechnology firms prioritize speed and platform scalability for clinical progression, and pharmaceutical companies seek predictable quality systems and capacity for late-stage scale-up. Integrating these segmentation perspectives provides a multidimensional map to prioritize investments, align service offerings, and design partnership models that reflect client-specific needs and modality attributes.

Interpreting how regional ecosystems, regulatory frameworks, and capacity development across the Americas, EMEA, and Asia-Pacific shape CDMO strategic positioning

Regional dynamics continue to influence strategic decisions across the CDMO landscape, with distinct drivers shaping demand and capability in each geography. In the Americas, robust biotech ecosystems, venture capital activity, and a concentration of late-stage clinical programs drive demand for scalable manufacturing and stringent regulatory compliance. This environment fosters closer collaboration between sponsors and manufacturing partners on clinical-to-commercial transition planning and necessitates investments in GMP-capable facilities, regulatory affairs expertise, and supply chain resilience.

In Europe, the Middle East & Africa, evolving regulatory harmonization efforts, a strong translational research base, and growing local biomanufacturing initiatives create opportunities for regional partners to offer specialized capabilities and navigate complex cross-border regulatory landscapes. Sponsors operating in these jurisdictions often balance access to localized scientific talent with the need for interoperable quality systems and regulatory dossiers that align with multiple authorities. The Asia-Pacific region is characterized by rapid capacity expansion, a maturing supplier base for reagents and components, and significant investments by governments and private entities to build domestic manufacturing capabilities. This has encouraged the development of cost-effective manufacturing options as well as opportunities for technology transfer and joint ventures. Across all regions, supply chain transparency, compliance consistency, and the ability to execute complex analytics remain critical selection criteria for sponsors seeking to mitigate geopolitical and operational risks.

Understanding the competitive levers and partnership models that enable CDMOs to differentiate through technical depth, integrated services, and customer-aligned commercial structures

Competitive dynamics among companies serving the nucleic acid therapeutics ecosystem are increasingly defined by depth of modality expertise, integrated service offerings, and the ability to de-risk clinical translation through proven regulatory engagement. Leading providers distinguish themselves by investing in platform technologies that enable faster process development, higher product quality, and streamlined scale-up pathways. Capacity alone no longer differentiates; rather, organizations that combine robust quality systems with advanced analytics and a track record of successful transfers enjoy a competitive edge.

Partnership models are evolving: strategic alliances, co-development agreements, and capacity reservation arrangements are common among organizations seeking to secure long-term pipeline throughput. Investment in talent-particularly in process scientists, analytical chemists, and regulatory specialists-is a critical differentiator, as is the ability to demonstrate successful comparability and validation work across multiple modalities. Mergers and acquisitions continue to be a lever for accessing niche capabilities quickly, but the integration of disparate quality systems and cultures requires deliberate planning. Finally, forward-looking companies prioritize customer-centric commercial models that offer transparency around capacity, pricing mechanisms that reflect value and risk, and collaborative governance structures to resolve program-level challenges efficiently.

Actionable strategic imperatives for executive leaders to strengthen partnerships, supply resilience, digital quality, and talent for reliable nucleic acid therapeutic development

Industry leaders and program sponsors must adopt a set of pragmatic actions to align operations, partnerships, and investment plans with the evolving realities of nucleic acid therapeutic development. First, prioritize co-development frameworks that formalize early-stage collaboration between sponsors and manufacturers to accelerate process transfer and minimize downstream surprises. Establishing joint milestones and decision gates clarifies expectations and reduces rework during scale-up. Second, invest in supply chain visibility and dual-sourcing strategies for critical raw materials and specialized reagents to manage exposure to trade policy shifts and single-source dependencies. Engaging in supplier qualification early will shorten timelines when alternate sources are needed.

Third, accelerate adoption of digital quality management and process analytical technologies to enable real-time monitoring and to support regulatory dossiers that emphasize lifecycle control. These investments reduce batch failure risk and enhance comparability assessments across manufacturing sites. Fourth, align commercial agreements with operational realities by incorporating capacity reservation clauses, risk-sharing provisions, and transparent escalation mechanisms for schedule adjustments. Fifth, build internal capabilities through targeted hiring and training programs that focus on analytics, aseptic processing, and regulatory strategy, while also evaluating strategic acquisitions or partnerships to fill capability gaps rapidly. By implementing these measures, organizations can reduce program risk, preserve development momentum, and create clearer pathways from discovery to commercial supply.

Explaining the mixed-methods research design combining primary expert interviews, technical validation, and triangulated secondary sources to ensure actionable and defensible insights

The underlying research methodology synthesizes multiple evidence streams to ensure robust, actionable insights. Secondary research involved systematic review of scientific literature, regulatory guidance documents, industry white papers, and technical standards to establish baseline technical and regulatory contexts. Primary research consisted of structured interviews with manufacturing leaders, process scientists, regulatory experts, procurement leads, and program managers to capture first-hand perspectives on operational challenges, supplier performance, and partnership dynamics. These qualitative inputs were complemented by technical validation exercises, including case study analyses of recent technology transfers, comparability efforts, and process scale-up examples.

Data triangulation was applied to corroborate themes across sources, ensuring that observed patterns in capacity expansion, quality system investments, and supply chain strategies were not isolated anecdotes. The methodology also incorporated scenario analysis to evaluate the operational implications of shifts such as tariff changes, regional capacity additions, and modality-specific manufacturing complexities. Where appropriate, the research team validated assumptions through follow-up interviews and document reviews to minimize bias. Together, these methods yield a defensible synthesis that balances technical specificity with strategic relevance for decision-makers in development, manufacturing, and commercial organizations.

Synthesizing how strategic alignment of capabilities, partnerships, and supply chain resilience determines successful translation of nucleic acid therapeutics from discovery to supply

The landscape for nucleic acid therapeutics manufacturing is in flux, driven by scientific innovation, evolving regulatory expectations, and shifting operational imperatives. Organizations that recognize the strategic nature of CDMO partnerships and that invest in integrated capabilities-spanning analytical excellence, adaptive manufacturing, and resilient supply chains-will be better positioned to convert scientific advances into reliable clinical and commercial supply. Transitional pains such as tariff-driven supply adjustments, regional capacity realignment, and the need for advanced analytics present operational challenges, but they also create opportunities for providers that can offer clear, validated pathways to de-risked scale-up.

Ultimately, success will favor those who approach manufacturing as a strategic asset rather than a transactional function, establishing collaborative governance, transparent commercial terms, and continuous improvement processes that accelerate program timelines and reduce technical and regulatory risk. By aligning investment priorities with modality-specific demands and by cultivating flexible, high-integrity supply chains, sponsors and providers can create more predictable development trajectories and realize the full potential of nucleic acid therapeutics across diverse therapeutic areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for scalable mRNA production platforms with optimized lipid nanoparticle formulation capabilities
  • 5.2. Integration of automated high-throughput screening in oligonucleotide manufacturing workflows to accelerate process development
  • 5.3. Adoption of continuous manufacturing for plasmid DNA to enhance yield consistency and reduce contamination risk
  • 5.4. Strategic partnerships between CDMOs and biotech firms for co-development of gene editing therapies using CRISPR-Cas systems
  • 5.5. Investment in modular single-use bioreactor systems tailored for viral vector production to support gene therapy pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type

  • 8.1. DNA Therapeutics
  • 8.2. RNA Therapeutics

9. Nucleic Acid Therapeutics CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing
  • 9.3. Packaging & Distribution
  • 9.4. Process Development & Optimization

10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications

  • 10.1. Genetic Disorders
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
  • 10.5. Rare Disorders

11. Nucleic Acid Therapeutics CDMO Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotechnology Firms
  • 11.3. Pharmaceutical Companies

12. Nucleic Acid Therapeutics CDMO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Therapeutics CDMO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Therapeutics CDMO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AGC Biologics Inc.
    • 15.3.2. Agilent Technologies, Inc.
    • 15.3.3. Ajinomoto Bio-Pharma Services
    • 15.3.4. Almac Group Ltd.
    • 15.3.5. Biomay AG
    • 15.3.6. BioSpring GmbH
    • 15.3.7. Catalent, Inc.
    • 15.3.8. Charles River Laboratories International, Inc.
    • 15.3.9. CordenPharma International GmbH
    • 15.3.10. Creative Biogene
    • 15.3.11. Danaher Corporation
    • 15.3.12. Eurofins Scientific SE
    • 15.3.13. Evonik Industries AG
    • 15.3.14. GenScript Biotech Corporation
    • 15.3.15. Lonza Group Ltd.
    • 15.3.16. Polypeptide Group AG
    • 15.3.17. Recipharm AB
    • 15.3.18. Rentschler Biopharma SE
    • 15.3.19. Samsung Biologics
    • 15.3.20. The Scripps Research Institute
    • 15.3.21. Touchlight Group
    • 15.3.22. Univercells Group
    • 15.3.23. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 198. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 199. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. GCC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 228. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 229. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. G7 NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 238. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 239. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NATO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET S